ClinicalTrials.gg
CompletedNCT03640949VAM-IHCAUpdated Mar 2, 2022Results posted

Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest

A Phase 2/3 interventional study of Vasopressin, Arginine and Methylprednisolone in Heart Arrest, sponsored by Lars Wiuff Andersen. Completed at 10 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.

Sponsored by Lars Wiuff Andersen · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
501
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Heart Arrest with a site in Denmark — 6 open to participants now, 11 under way, none of them phase 3. Heart Arrest · Denmark.

Enrollment
11th of 26
501 · median 274
Started
2018
with 6 others
Phase 2/3
Only one
of the 36
Registered
17th of 36
by date
Lead sponsor
4 of 36
Lars Wiuff Andersen

Among the 36 studies in Heart Arrest with a site in Denmark, this one is the 11th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2018, is the only one in phase 2/3, and was the 17th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

6 of the 36 studies in Heart Arrest with a site in Denmark are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Heart Arrest with a site in Denmark, or all of them as a file.
02

Study summary

This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of vasopressin and methylprednisolone during adult in-hospital cardiac arrest. There will be ten enrolling sites in Denmark. 492 adult patients with in-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled. The primary outcome is return of spontaneous circulation and key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.

03

Conditions studied

  • Heart Arrest

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In-hospital cardiac arrest
  2. Age ≥ 18 years
  3. Received at least one dose of adrenaline during cardiopulmonary resuscitation

Exclusion criteria

Exclusion Criteria:

  1. Clearly documented "do-not-resuscitate" order prior to the cardiac arrest
  2. Prior enrollment in the trial
  3. Invasive mechanical circulatory support at the time of the cardiac arrest
  4. Known or suspected pregnancy at the time of the cardiac arrest
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
501 participants (actual)

Study arms

  • Experimental
    Vasopressin and methylprednisolone

    The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).

    Drug: Vasopressin, Arginine · Drug: Methylprednisolone

  • Placebo comparator
    Placebo

    The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl ("normal saline") from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl.

    Drug: NaCl

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Return of Spontaneous Circulation

    Return of spontaneous circulation is defined as spontaneous circulation with no further need for chest compressions sustained for at least 20 minutes

    Time frame: During the cardiac arrest, an average of 20 minutes

Secondary outcomes

  1. Number of Participants That Survived 30 Days

    Time frame: At 30 days

  2. Number of Participants With a Favorable Neurological Outcome at 30 Days

    A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.

    Time frame: At 30 days

Other outcomes

  1. Vasopressor-free Days

    Vasopressor-free days will be defined as the number of days within the first 7 days after the cardiac arrest where the patient is not receiving vasopressors and is alive.

    Time frame: 7 days

  2. Invasive Ventilation-free Days

    Invasive ventilation-free days will be defined as the number of days within the first 7 days after the cardiac arrest where the patient is not receiving invasive ventilation and is alive.

    Time frame: 7 days

  3. Sequential Organ Failure Assessment (SOFA) Score at 24, 48 and 72 Hours

    The SOFA score is a validated and widely used measure of organ failure assessing the respiratory, nervous, cardiovascular, hepatic, coagulation, and renal systems. We will assess both the cardiovascular sub score as well as the overall SOFA score.

    Time frame: 24, 48 and 72 hours

  4. Hospital Disposition

    Hospital disposition (e.g. home, rehabilitation, nursing home, hospice) will be defined at the time of discharge from the initial acute care hospital.

    Time frame: At hospital discharge, up to 1 year

  5. Survival

    Time frame: At 90 days, 180 days, and 1 year

  6. Favorable Neurological Outcome

    A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.

    Time frame: At 90 days, 180 days, and 1 year

  7. Modified Rankin Scale (mRS)

    The mRS is a 7-point scale, ranging from 0 (no symptoms) to 6 (dead), assessing the degree of disability and dependence after a neurological injury such as stroke or cardiac arrest. A good outcome will be defined as a mRS of 0 to 3 and a poor outcome as 4 to 6.

    Time frame: At 30 days, 90 days, 180 days, and 1 year

  8. Glasgow Outcome Scale Extended (GOSE)

    The GOSE is a 8-point scale that is an extension of the Glasgow Outcomes Scale (which is identical to the CPC, only with inverse scores) where the scores 1, 2 and 3 from the CPC score is divided into two.

    Time frame: At 30 days, 90 days, 180 days, and 1 year

  9. Health-related Quality of Life (EQ-5D-5L)

    The EQ-5D-5L is a well-established measure of health-related quality of life that is quantified as a utility (i.e. a measure of quality of life between 0 and 1).

    Time frame: At 30 days, 90 days, 180 days, and 1 year

07

Results

Posted Jan 11, 2022

Participant flow

Participant flow — Overall Study
MilestoneVasopressin and MethylprednisolonePlacebo
Started237264
Completed237264
Not completed00

Outcome measures

PrimaryNumber of Participants With Return of Spontaneous Circulation

Return of spontaneous circulation is defined as spontaneous circulation with no further need for chest compressions sustained for at least 20 minutes

Time frame:
During the cardiac arrest, an average of 20 minutes
Reported as:
Number · participants
Number of Participants With Return of Spontaneous Circulation
participantsVasopressin and MethylprednisolonePlacebo
Number of Participants With Return of Spontaneous Circulation10086
SecondaryNumber of Participants That Survived 30 Days
Time frame:
At 30 days
Reported as:
Count of participants · Participants
Number of Participants That Survived 30 Days
ParticipantsVasopressin and MethylprednisolonePlacebo
Number of Participants That Survived 30 Days2331
SecondaryNumber of Participants With a Favorable Neurological Outcome at 30 Days

A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.

Time frame:
At 30 days
Reported as:
Count of participants · Participants
Number of Participants With a Favorable Neurological Outcome at 30 Days
ParticipantsVasopressin and MethylprednisolonePlacebo
Number of Participants With a Favorable Neurological Outcome at 30 Days1820
Other pre-specifiedVasopressor-free Days

Vasopressor-free days will be defined as the number of days within the first 7 days after the cardiac arrest where the patient is not receiving vasopressors and is alive.

Time frame:
7 days

Results for this outcome have not been posted.

Other pre-specifiedInvasive Ventilation-free Days

Invasive ventilation-free days will be defined as the number of days within the first 7 days after the cardiac arrest where the patient is not receiving invasive ventilation and is alive.

Time frame:
7 days

Results for this outcome have not been posted.

Other pre-specifiedSequential Organ Failure Assessment (SOFA) Score at 24, 48 and 72 Hours

The SOFA score is a validated and widely used measure of organ failure assessing the respiratory, nervous, cardiovascular, hepatic, coagulation, and renal systems. We will assess both the cardiovascular sub score as well as the overall SOFA score.

Time frame:
24, 48 and 72 hours

Results for this outcome have not been posted.

Other pre-specifiedHospital Disposition

Hospital disposition (e.g. home, rehabilitation, nursing home, hospice) will be defined at the time of discharge from the initial acute care hospital.

Time frame:
At hospital discharge, up to 1 year

Results for this outcome have not been posted.

Other pre-specifiedSurvival
Time frame:
At 90 days, 180 days, and 1 year

Results for this outcome have not been posted.

Other pre-specifiedFavorable Neurological Outcome

A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.

Time frame:
At 90 days, 180 days, and 1 year

Results for this outcome have not been posted.

Other pre-specifiedModified Rankin Scale (mRS)

The mRS is a 7-point scale, ranging from 0 (no symptoms) to 6 (dead), assessing the degree of disability and dependence after a neurological injury such as stroke or cardiac arrest. A good outcome will be defined as a mRS of 0 to 3 and a poor outcome as 4 to 6.

Time frame:
At 30 days, 90 days, 180 days, and 1 year

Results for this outcome have not been posted.

Other pre-specifiedGlasgow Outcome Scale Extended (GOSE)

The GOSE is a 8-point scale that is an extension of the Glasgow Outcomes Scale (which is identical to the CPC, only with inverse scores) where the scores 1, 2 and 3 from the CPC score is divided into two.

Time frame:
At 30 days, 90 days, 180 days, and 1 year

Results for this outcome have not been posted.

Other pre-specifiedHealth-related Quality of Life (EQ-5D-5L)

The EQ-5D-5L is a well-established measure of health-related quality of life that is quantified as a utility (i.e. a measure of quality of life between 0 and 1).

Time frame:
At 30 days, 90 days, 180 days, and 1 year

Results for this outcome have not been posted.

Adverse events

Collected over Through hospital admission up to 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vasopressin and Methylprednisolone214/237 (90.3%)0/237 (0%)0/237 (0%)
Placebo233/264 (88.3%)0/264 (0%)0/264 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vasopressin and MethylprednisolonePlaceboTotal
Mean71 ± 1370 ± 1271 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)Vasopressin and MethylprednisolonePlaceboTotal
Female8990179
Male148174322
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Vasopressin and MethylprednisolonePlaceboTotal
Count of participants——0
08

Study locations

10 sites
  • Aalborg University Hospital
    Aalborg, Denmark
  • Aarhus University Hospital
    Aarhus, Denmark
  • Copenhagen University Hospital - Rigshospitalet
    Copenhagen, Denmark
  • Copenhagen University Hospital - Gentofte
    Hellerup, Denmark
  • Copenhagen University Hospital - Herlev
    Herlev, Denmark
  • Horsens Regional Hospital
    Horsens, Denmark
  • Zealand University Hospital - Køge
    Køge, Denmark
  • Odense University Hospital
    Odense, Denmark
  • Randers Regional Hospital
    Randers, Denmark
  • Viborg Regional Hospital
    Viborg, Denmark
09

References and documents

Publications

  • Andersen LW, Isbye D, Kjaergaard J, Kristensen CM, Darling S, Zwisler ST, Fisker S, Schmidt JC, Kirkegaard H, Grejs AM, Rossau JRG, Larsen JM, Rasmussen BS, Riddersholm S, Iversen K, Schultz M, Nielsen JL, Lofgren B, Lauridsen KG, Solling C, Paelestik K, Kjaergaard AG, Due-Rasmussen D, Folke F, Charlot MG, Jepsen RMHG, Wiberg S, Donnino M, Kurth T, Hoybye M, Sindberg B, Holmberg MJ, Granfeldt A. Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2021 Oct 26;326(16):1586-1594. doi: 10.1001/jama.2021.16628. PubMed 34587236 ↗
  • Andersen LW, Sindberg B, Holmberg M, Isbye D, Kjaergaard J, Zwisler ST, Darling S, Larsen JM, Rasmussen BS, Lofgren B, Lauridsen KG, Paelestik KB, Solling C, Kjaergaard AG, Due-Rasmussen D, Folke F, Charlot MG, Iversen K, Schultz M, Wiberg S, Jepsen RMHG, Kurth T, Donnino M, Kirkegaard H, Granfeldt A. Vasopressin and methylprednisolone for in-hospital cardiac arrest - Protocol for a randomized, double-blind, placebo-controlled trial. Resusc Plus. 2021 Jan 30;5:100081. doi: 10.1016/j.resplu.2021.100081. eCollection 2021 Mar. PubMed 34223347 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Six months after the publication of the last results, all de-identified individual patient data will be made available for data sharing. Procedures, including re-coding of key variables, will be put in place to allow for complete de-identification of the data. Data will be completely anonymized according to Danish law. All relevant trial-related documents, including the protocol, data dictionary, and the main statistical code, will be shared along with the data. There will be no predetermined end date for the data sharing.

Supporting information: Study protocol, Statistical analysis plan

Access criteria: Data will be available for any research purpose to all interested parties who have approval from an independent review committee and who have a methodological sound proposal as determined by the steering committee of the current trial. Only the methodological qualities and not the purpose or objective of the proposal will be considered. Interested parties will be able to request the data by contacting the principal investigator. Authorship of publications emerging from the shared data will follow standard authorship guidelines from the International Committee of Medical Journal Editors and might or might not include authors from the steering committee depending on the nature of their involvement.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Jan 2021, 28 months.

Results were first posted in Jan 2022, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2018
First posted
Aug 21, 2018
StartActual
Sep 17, 2018
Primary completionActual
Jan 21, 2021
CompletionActual
Jan 21, 2022
Results first posted
Jan 11, 2022
Last update
Mar 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03640949
Lead sponsor
Lars Wiuff Andersen
Responsible party
Lars Wiuff Andersen (Associate Professor, Aarhus University Hospital) — Sponsor-investigator
First posted
Aug 21, 2018
Start date
Sep 17, 2018
Primary completion
Jan 21, 2021
Completion
Jan 21, 2022
Results posted
Jan 11, 2022
Last update
Mar 2, 2022

Study contacts

Lars W Andersen, MD, MPH, PhD, DMSc
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylprednisolone

Start the discussion